About Us

Elea has been developing products, medications and treatments for every medical specialty for over 80 years. A whole life accompanying yours.

&

Mission

Our mission is to boost constant innovation in the development of cutting-edge medicine and treatments that enhance people’s life quality, from Argentina, to the world.

Vision

Being the most widely present pharmaceutical company in households, committed to all life stages of every person.

Our
Values

People, science and technology have made unthinkable changes, thus it was necessary to rethink us, and that is what we did at Elea, so that you move forward with your life.

Proximity

to every household, at every moment.
to every household, at every moment.

Flexibility

To be able to think and rethink the path.
We adapt to the various circumstances that arise providing timely responses, because we see changes as new challenges to be met.

Commitment

To the new ideas whilst maintaining the same ideals.
We are deeply committed to innovation and continued growth, maintaining the high quality, safety and technology standards that have always been our pillars.

Innovation

to always go further.
We dare do what nobody else does. We are at the forefront in each one of our areas so as to always be the first.

Track Record

We boast over 80 years of history that endorse what we do. A history built on the bases of trust and experiences. A track record based on integrity and transparency as the key values to our success and that of the pharmaceutical industry.

A tour along our history

Over 80 years researching and developing products and medications to accompany people in every stage of their life.

Loading

ELEA IS SET UP

1939

ELEA IS SET UP

Laboratorio Elea is established. Phoenix starts in the medicine specialties sector.

Loading

FIRST ANTIBIOTICS

1945

Phoenix launches the first few antibiotics in the country (penicillin and streptomycin).

SALK VACCINE

1959

Phoenix distributes Salk vaccine against poliomyelitis in Argentina.

Loading

SYNTHESIS PLANT

1962

The first Synthesis Plant is set up in Elea.

Loading

OSMOTIC TECHNOLOGY

1986

Phoenix is the first and only Argentine lab to use osmotic technology, a prolonged drug release system.

Loading

ANUSOL

1987

Anusol® is granted N°1 ANMAT certificate, becoming the country’s first registration.

Loading

PARKE DAVIS LICENSE

1989

Warner Lambert (Parke Davis & Chicle Adams) becomes G&MS.A. (Golosinas & Medicamentos S.A.).

Loading

RECOMBINANT STREPTOKINASE

1994

Elea registers recombinant Streptokinase for the treatment of clots.

IOR-T3 ANTIBODY

1994

Elea becomes the first national pharmaceutical company to register the first monoclonal antibody for the treatment of acute rejection in renal transplant. (IOR-T3)

Loading

LIQUID FILLER

1995

Elea incorporates the most modern liquid filler in the country.

Loading

NEW INDUSTRIAL PLANT

2000

Elea inaugurates the new Industrial Plant equipped with state-of-the-art technology.

Loading

VDM PLANT

2002


Phoenix acquires Novartis Plant in Villa de Mayo, Buenos Aires.

ANALYTICAL LABORATORIES

2004

New Development & Quality Control analytical laboratories are opened in Elea.

Loading

LEPTOSPIROSIS VACCINE

2006

Elea/Caif bring to the market the only vaccine against Leptospirosis

Loading

ONCOLOGY LINE

2007


The first oncology line product is launched.

HEBERPROT P® TREATMENT

2009

Introduction of the first and only treatment for Diabetic Foot ulcers ((HeberProt P®).

Loading

RACOTUMOMAB STUDY

2009

Multinational, Phase III Study for Racotumomab begins.

Loading

GSK

2010

Phoenix is acquired by GSK.

Loading

OPHTHALMOLOGY LINE

2010

Incorporation of the ophthalmology line.

CMC LICENSE

2011


Incorporation of Merck Serono’s CMC product license.

Loading

FIRST MONOCLONAL ANTIBODIES PLANT

2012

Creation of the first monoclonal antibodies plant with the participation of Laboratorio Elea, PharmaADN and Biogénesis-Bagó.

Loading

LUNG CANCER VACCINE

2013

Vaxira®, first therapeutic vaccine for lung cancer treatment. This results from 20 years of joint development with Cuba’s Molecular Immunology Center.

Loading

RITUXIMAB MONOCLONAL ANTIBODY

2013

Elea develops and approves the first Rituximab monoclonal antibody in Argentina.

Loading

MEDISEAL SOLIDS

2014

New technology in Mediseal solid conditioning is incorporated to Elea plant.

TREATMENT FOR ONCOLOGY SURGERIES

2015

 ONCOLOGY SURGERIESWe developed the first Desmopressin for the perioperative treatment of bleeding in oncology related surgical procedures.

Loading

BEVACIZUMAB MONOCLONAL ANTIBODY

2016

We launch the first Bevacizumab monoclonal antibody in Argentina.

ELEA PHOENIX

2017

Elea merges with Phoenix.

Loading

LUMIERE

2018

We develop the first and only intravitreal Bevacizumab (Lumiere®) in the world for the treatment of age-related degenerative maculopathy.

UNIFICATION OF PRODUCTION PLANTS

2019

Elea and Phoenix plants are unified incorporating new sector.

Loading

1A-116 DEVELOPMENT

2019

Jointly with Chemo/ Universidad de Quilmes we participated in the development of the first synthetic molecule (1A-116) developed through the use of supercomputers. In 2020, we will conduct clinical trials in human beings with different diseases.

Loading

ELEA ACQUIRES NEW PRODUCTS

2020

Elea acquires new products: Adermicina, Bronquisedan, Biogrip, Falgos, Minicam, Ratisalill, Karidium and Deltisona B from the multinational Sanofi, and Hepatalgina, from the multinational Takeda.

Loading

ELEA

2020

Elea Phoenix becomes empowered and strengthened, after 80 years of history, by relaunching its corporate identity.

Loading

LATAM EXPANSION

2021

Elea expands into LATAM and sets up subsidiaries in Chile, Peru Ecuador and Colombia

Loading

NICHI-IKO ALLIANCE

2021

Elea has established its first international strategic Alliance with NICHI-IKO

Loading

ELEA IS SET UP

FIRST ANTIBIOTICS

SALK VACCINE

SYNTHESIS PLANT

OSMOTIC TECHNOLOGY

ANUSOL

PARKE DAVIS LICENSE

RECOMBINANT STREPTOKINASE

IOR-T3 ANTIBODY

LIQUID FILLER

NEW INDUSTRIAL PLANT

VDM PLANT

ANALYTICAL LABORATORIES

LEPTOSPIROSIS VACCINE

ONCOLOGY LINE

HEBERPROT P® TREATMENT

RACOTUMOMAB STUDY

GSK

OPHTHALMOLOGY LINE

CMC LICENSE

FIRST MONOCLONAL ANTIBODIES PLANT

LUNG CANCER VACCINE

RITUXIMAB MONOCLONAL ANTIBODY

MEDISEAL SOLIDS

TREATMENT FOR ONCOLOGY SURGERIES

BEVACIZUMAB MONOCLONAL ANTIBODY

ELEA PHOENIX

LUMIERE

UNIFICATION OF PRODUCTION PLANTS

1A-116 DEVELOPMENT

ELEA ACQUIRES NEW PRODUCTS

ELEA

LATAM EXPANSION

NICHI-IKO ALLIANCE

1730
1740
1750
1760
1770
1780
1790
1800
1810
1820
1830
1840
1850
1860
1870
1880
1890
1900
1910
1920
1930
1940
1950
1960
1970
1980
1990
2000
2010
2020
2030
2040
2050
2060
2070
2080
2090
2100
2110
2120
2130
2140
2150
2160
2170
2180
2190
2200
2210
2220
1918
1919
1921
1922
1923
1924
1925
1926
1927
1928
1929
1931
1932
1933
1934
1935
1936
1937
1938
1939
1941
1942
1943
1944
1945
1946
1947
1948
1949
1951
1952
1953
1954
1955
1956
1957
1958
1959
1961
1962
1963
1964
1965
1966
1967
1968
1969
1971
1972
1973
1974
1975
1976
1977
1978
1979
1981
1982
1983
1984
1985
1986
1987
1988
1989
1991
1992
1993
1994
1995
1996
1997
1998
1999
2001
2002
2003
2004
2005
2006
2007
2008
2009
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2025
2026
2027
2028
2029
2031
2032
2033
2034
2035
2036
2037
2038
2039
2041

Compliance

Elea regards ethics and integrity as its fundamental pillar which are present in every relationship with clients, suppliers, collaborators and private and public entities.

Our company is strongly committed to holding business following these values. To this end, we have implemented internal procedures supporting this dynamic, such as our Code of Ethics, Anti-corruption, Antitrust and Fair Competition Policies and our continuous training programs in Compliance.

Sustainability

For us, sustainability and integrity go hand in hand, thus, we are committed to mitigating the environmental impact we generate. We aim to promote commitment to sustainability in our culture and we implement new and more sustainable technologies.

We are constantly looking for opportunities to minimize our carbon print, reduce waste and raise awareness on water and energy conservation within our site.

Strategic Alliances

Acceder
Usted está accediendo a una sección del sitio que contiene información para los profesionales de la salud

Aquí se encuentra orientación específica para el uso adecuado de los medicamentos que se obtienen bajo prescripción médica.

Ante cualquier duda sobre condiciones médicas particulares es pertinente consultar a un profesional de la salud.

Acceder Acceder

Our Plant

Elea Av. General Juan Gregorio Lemos 2809 – Villa de Mayo, Buenos Aires

Contact

Contact us by completing this form:

Elea Teléfono 0800.333.3532 Elea Email info@elea.com

Fields marked with * must be completed